Skip to main content
NovartisPartnership

Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis has entered into a licensing agreement with China-based Abogen Biosciences for its early-stage experimental treatment for autoimmune disease, a deal worth up to $7.8 billion.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

In this article Novartis has signed a deal worth up to $7.8 billion, in the latest of a flurry of tie-ups between Big Pharma and Chinese biotechs. The Swiss pharma major is entering a licensing agreement with China-based Abogen Biosciences for its lead asset, an early-stage experimental treatment for autoimmune disease, Abogen said in a statement on Friday. China offers Western biopharma companies hopes of finding their next blockbuster drug, as patents on top-selling drugs, which generate hundreds of billions in sales, face a "patent cliff" in the early 2030s, Novartis' normally stable shares fell last month by the most since 1987 following several clinical trial setbacks, raising questions about its ability to develop new drugs to offset the looming patent expirations. As part of its Abogen deal, the company will pay $575 million upfront for the global rights to the Chinese company's messenger RNA therapy, with an additional $7.2 billion in milestone payments. It will also have the exclusive option to license Abogen's assets developed on its RNA platform. Novartis' announcement comes after Danish weight loss drug maker Novo announced earlier this week an exclusive licensing agreement with Hengrui Pharma for an early-stage, once-weekly GLP-1/GIP pill for as much as $2.6 billion. Novo, whose shares have plummeted over the past two years amid intensifying competition in the...

Keep reading with a free account

The rest of this article, and every signal for Novartis, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Amount named
$7.8B
Product
experimental treatment for autoimmune disease
Takes effect
Oct 2, 2026
Location
China

Companies

  • Abogen BiosciencesPartnerabogenbio.com

The full record

From the Signal API record

Numbers

Amount named in the story
$7.8B

Topics and mentions

Product tags

  • general technology
  • medical

Extraction

Confidence
90%
Detected
Oct 2, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b52ef2b7-aa0b-4add-9a7e-f2f2d5d06711 returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "b52ef2b7-aa0b-4add-9a7e-f2f2d5d06711",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-02T11:18:16+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/10/02/novartis-abogen-china-biotech-deal.html",
    "title": "Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals",
    "excerpt": "In this article Novartis has signed a deal worth up to $7.8 billion, in the latest of a flurry of tie-ups between Big Pharma and Chinese biotechs. The Swiss pharma major is entering a licensing agreement with China-based Abogen Biosciences for its lead asset, an early-stage experimental treatment for autoimmune disease, Abogen said in a statement on Friday. China offers Western biopharma companies hopes of finding their next blockbuster drug, as patents on top-selling drugs, which generate hundreds of billions in sales, face a \"patent cliff\" in the early 2030s, Novartis' normally stable shares fell last month by the most since 1987 following several clinical trial setbacks , raising questions about its ability to develop new drugs to offset the looming patent expirations. As part of its Abogen deal, the company will pay $575 million upfront for the global rights to the Chinese company's messenger RNA therapy, with an additional $7.2 billion in milestone payments. It will also have the exclusive option to license Abogen's assets developed on its RNA platform. Novartis' announcement comes after Danish weight loss drug maker Novo announced earlier this week an exclusive licensing agreement with Hengrui Pharma for an early-stage, once-weekly GLP-1/GIP pill for as much as $2.6 billion. Novo, whose shares have plummeted over the past two years amid intensifying competition in the...",
    "product": "experimental treatment for autoimmune disease",
    "summary": "Novartis has entered into a licensing agreement with China-based Abogen Biosciences for its early-stage experimental treatment for autoimmune disease, a deal worth up to $7.8 billion.",
    "location": "China",
    "planning": true,
    "image_url": "https://image.cnbcfm.com/api/v1/image/108328514-1782803221665-gettyimages-2152722520-dsc00854.jpeg?v=1782803282&w=1920&h=1080",
    "confidence": 0.9,
    "product_data": {
      "name": "experimental treatment for autoimmune disease",
      "full_text": "an early-stage experimental treatment for autoimmune disease",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-02T11:18:16Z",
    "location_data": [
      {
        "region": "Eastern Asia",
        "country": "China",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-02",
    "article_sentence": "The Swiss pharma major is entering a licensing agreement with China-based Abogen Biosciences for its lead asset, an early-stage experimental treatment for autoimmune disease, Abogen said in a statement on Friday.",
    "amount_normalized": 7800000000,
    "related_company_name": "Abogen Biosciences",
    "related_company_domain": "abogenbio.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.